Sunday, 23 August 2026European Markets
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Work with this data → vianewsagency.com

NYXOAH Stock Is 30% Up In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of NYXOAH (BEL 20: NYXH.BR) rose by a staggering 30.76% in 21 sessions from €6.21 to €8.12 at 02:22 EST on Monday, after two consecutive sessions in a row of losses. BEL 20 is jumping 0.06% to €3,826.30, following the last session's upward trend.

NYXOAH's last close was €8.12, 52.57% below its 52-week high of €17.12.

About NYXOAH

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Earnings Per Share

As for profitability, NYXOAH has a trailing twelve months EPS of €-1.21.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -23.22%.

Growth Estimates Quarters

The company's growth estimates for the current quarter and the next is a negative 26.9% and a negative 78.9%, respectively.

More news about NYXOAH (NYXH.BR).